Present evidence on the value of HPV testing for cervical cancer screening: a model-based exploration of the (costm)effectiveness
1997

HPV Testing for Cervical Cancer Screening

publication Evidence: moderate

Author Information

Author(s): M van Ballegooijen, ME van den Akker-van Marie, PG Warmerdam, CJLM Meijer, JMM Walboomers, JDF Habbema

Primary Institution: Erasmus University, Rotterdam, The Netherlands; Free University Hospital, Amsterdam, The Netherlands

Hypothesis

Is the current evidence sufficient to recommend HPV screening for cervical cancer?

Conclusion

The study suggests that while HPV testing may improve cervical cancer screening, more extensive longitudinal studies are needed to confirm its cost-effectiveness.

Supporting Evidence

  • HPV is the main risk factor for invasive cervical cancer.
  • Model version A predicted a higher mortality reduction from HPV screening compared to Pap smear screening.
  • Model version B showed that HPV screening may not be as effective as Pap smear screening.

Takeaway

This study looks at whether testing for HPV can help find cervical cancer earlier. It finds that we need more research to be sure it's a good idea.

Methodology

The study used a cervical cancer screening model that incorporated HPV infection as a precursor to cervical intraepithelial neoplasia (CIN).

Potential Biases

The models constructed may not fully account for the variability in HPV infection duration and test sensitivity.

Limitations

The study relies on small follow-up studies and limited design strength, which may not provide definitive conclusions.

Participant Demographics

Women aged 30-60 years were the focus of the study.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication